Somatostatin Analogues

Alicja Hubalewska-Dydejczyk, PhD, MD, is Professor of Endocrinology and Nuclear Medicine, and Head of the Chair and Department of Endocrinology at the Jagiellonian University's Medical College (Cracow, Poland).Alberto Signore, MD, is Professor of Nuclear Medicine and Physician in the Department of Medical-Surgical Sciences and Translational Medicine of the Faculty of Medicine and Psychologu of "Sapienza" University in Rome, Italy.Marion de Jong, PhD, is Professor of Nuclear Biology at the Departments of Nuclear Medicine and Radiology of the Erasmusc MC in Rotterdam, The Netherlands.Rudi A. Dierckx, PhD, is Head of the Department of Nuclear Medicine and Molecular Imaging at the University Medical Center Groningen, University of Groningen, the Netherlands.John Buscombe, MD, is a Consultant Physician in Nuclear Medicine Addenbrooke's Hospital (Cambridge, UK) and Honorary Professor in Nuclear Medicine at the University of Pretoria, South Africa.Christophe Van de Wiele, PhD, is Full Professor at the University of Ghent, Belgium.

• Contributors viiiPreface xiiAcknowledgements xv1 Somatostatin: The History of Discovery 1Malgorzata Trofimiuk‐Müldner and Alicja Hubalewska‐Dydejczyk2 Physiology of Endogenous Somatostatin Family: Somatostatin Receptor Subtypes, Secretion, Function and Regulation, and Organ Specific Distribution 6Marily Theodoropoulou3 Somatostatin Receptors in Malignancies and Other Pathologies 21Marco Volante, Adele Cassenti, Ida Rapa, Luisella Righi, and Mauro Papotti4 The Use of Radiolabeled Somatostatin Analogue in Medical Diagnosis: Introduction 31Alberto Signore4.1 Somatostatin Receptor Scintigraphy‐SPECT 35Renata Mikołajczak and Alberto Signore4.2 Molecular Imaging of Somatostatin Receptor‐Positive Tumors Using PET/CT 55Richard P. Baum and Harshad R. Kulkarni4.3 Other Radiopharmaceuticals for Imaging GEP‐NET 75Klaas Pieter Koopmans, Rudi A. Dierckx, Philip H. Elsinga, Thera P. Links, Ido P. Kema, Helle-Brit Fiebrich, Annemieke M.E. Walekamp, Elisabeth G.E. de Vries, and Adrienne H. Brouwers4.4 The Place of Somatostatin Receptor Scintigraphy in Clinical Setting: Introduction 86Alicja Hubalewska‐Dydejczyk4.4.1 Somatostatin Receptor Scintigraphy in Management of Patients with Neuroendocrine Neoplasms 90Anna Sowa‐Staszczak, Agnieszka Stefańska, Agata Jabrocka‐Hybel, and Alicja Hubalewska‐Dydejczyk4.4.2 The Place of Somatostatin Receptor Scintigraphy and Other Functional Imaging Modalities in the Setting of Pheochromocytoma and Paraganglioma 112Alicja Hubalewska‐Dydejczyk, Henri J.L.M. Timmers, and Malgorzata Trofimiuk‐Müldner4.4.3 Somatostatin Receptor Scintigraphy in Medullary Thyroid Cancer 127Anouk N.A. van der Horst‐Schrivers, Adrienne H. Brouwers, and Thera P. Links4.4.4 Somatostatin Receptor Scintigraphy in Other Tumors Imaging 135Malgorzata Trofimiuk‐Müldner and Alicja Hubalewska‐Dydejczyk4.4.5 Somatostatin Receptor Scintigraphy in Inflammation and Infection Imaging 153Alberto Signore, Kelly Luz Anzola Fuentes, and Marco Chianelli5 Somatostatin Analogues in Pharmacotherapy: Introduction 164Wouter W. de Herder5.1 Somatostatin Analogues in Pharmacotherapy 166Wouter W. de Herder5.2 Pituitary Tumor Treatment with Somatostatin Analogues 169Alicja Hubalewska-Dydejczyk, Aleksandra Gilis-Januszewska, and Malgorzata Trofimiuk-Müldner5.3 Somatostatin Analogues in Pharmacotherapy of Gastroenteropancreatic Neuroendocrine Tumors 189Frédérique Maire and Philippe Ruszniewski5.4 Somatostatin Analogue Use in Other than Endocrine Tumor Indications 198Aleksandra Gilis‐Januszewska, Malgorzata Trofimiuk‐Müldner, Agata Jabrocka‐Hybel,, and Dorota Pach6 Peptide Receptor Radionuclide Therapy Using Radiolabeled Somatostatin Analogues: An Introduction 207John Buscombe6.1 Somatostatin Analogues and Radionuclides Used in Therapy 214Esther I. van Vliet, Boen L.R. Kam, Jaap J.M. Teunissen, Marion de Jong, Eric P. Krenning, and Dik J. Kwekkeboom6.2 PRRT Dosimetry 230Mark Konijnenberg6.3 Peptide Receptor Radionuclide Therapy (PRRT): Clinical Application 252Lisa Bodei, and Giovanni Paganelli6.4 Duo‐PRRT of Neuroendocrine Tumors Using Concurrent and Sequential Administration of Y‐90‐ and Lu‐177‐Labeled Somatostatin Analogues 264Richard P. Baum and Harshad R. Kulkarni6.5 N onsystemic Treatment of Liver Metastases from Neuroendocrine Tumor 273Daniel Putzer, Gerlig Widmann, Dietmar Waitz, Werner Jaschke, and Irene J. Virgolini6.6 Peptide Receptor Radionuclide Therapy: Other Indications 282Agnieszka Stefańska, Alicja Hubalewska‐Dydejczyk, Agata Jabrocka‐Hybel, and Anna Sowa‐Staszczak7 Somatostatin Analogs: Future Perspectives and Preclinical Studies—Pansomatostatins 291Aikaterini Tatsi Berthold A. Nock, Theodosia Maina, and Marion de Jong8 Radiolabeled Somatostatin Receptor Antagonists 305Melpomeni Fani and Helmut R. Maecke9 Cortistatins and Dopastatins 321Manuela Albertelli and Diego FeroneIndex 000